TScan Therapeutics Income Statement (2020-2026) | TCRX

Income Statement Jun2020 Sep2020 Dec2020 Mar2021 Jun2021 Sep2021 Dec2021 Mar2022 Jun2022 Sep2022 Dec2022 Mar2023 Jun2023 Sep2023 Dec2023 Mar2024 Jun2024 Sep2024 Dec2024 Mar2025 Jun2025 Sep2025 Dec2025 Mar2026
Revenue & cost
Revenue (Quarter)
2.85M2.41M2.85M3.02M4.06M3.36M3.10M5.80M3.15M3.89M7.21M0.57M0.54M1.05M0.67M2.17M3.08M2.51M2.57M0.98M
Operating items
Research & Development (Quarter)
10.80M14.21M12.61M14.69M14.49M15.03M15.60M21.78M21.23M22.74M22.41M24.86M26.88M26.26M29.35M29.79M32.63M31.69M20.04M21.90M
Selling, General & Administrative (Quarter)
2.73M4.05M4.45M4.49M4.81M4.91M6.14M7.77M6.53M5.89M6.16M7.08M7.77M7.41M8.02M8.63M9.10M7.87M6.39M8.22M
Operating Expenses (Quarter)
13.53M18.25M17.06M19.18M19.30M19.94M21.74M29.55M27.76M28.64M28.57M31.94M34.65M33.67M37.38M38.42M41.73M39.56M26.43M30.12M
Operating Income (Quarter)
-10.68M-15.84M-14.20M-16.16M-15.25M-16.58M-18.65M-22.74M-24.61M-24.75M-21.36M-31.37M-34.11M-32.62M-36.71M-36.25M-38.65M-37.05M-23.86M-29.14M
EBIT (Quarter)
-10.68M-15.84M-14.20M-16.16M-15.25M-16.58M-18.65M-22.74M-24.61M-24.75M-21.36M-31.37M-34.11M-32.62M-36.71M-36.25M-38.65M-37.05M-23.86M-29.14M
Non-operating items
Interest & Investment Income (Quarter)
0.01M0.00M0.00M0.01M0.15M0.53M0.90M1.14M1.53M2.73M2.60M2.19M3.40M3.69M-9.24M-0.06M2.39M2.04M-7.28M1.16M
Other Non Operating Income (Quarter)
0.01M0.15M0.33M-0.07M0.18M0.56M1.75M1.74M1.23M2.45M2.73M0.90M2.12M1.70M1.34M0.88M0.47M
Net income details
EBT (Quarter)
-32.91M-25.29M-16.32M-16.16M-15.10M-16.25M-19.55M-22.56M-24.05M-23.00M-25.25M-30.14M-31.66M-29.89M-46.73M-36.98M-36.95M-35.71M-32.19M-28.67M
Profit After Tax (Quarter)
-10.67M-15.84M-14.18M-16.20M-15.10M-16.25M-18.70M-22.56M-24.05M-23.00M-19.62M-30.14M-31.66M-29.89M-35.81M-34.13M-36.95M-35.71M-23.01M-28.67M
Income from Continuing Operations (Quarter)
-32.91M-25.29M-16.32M-16.16M-15.10M-16.25M-19.55M-22.56M-24.05M-23.00M-25.25M-30.14M-31.66M-29.89M-46.73M-36.98M-36.95M-35.71M-32.19M-28.67M
Consolidated Net Income (Quarter)
-32.91M-25.29M-16.32M-16.16M-15.10M-16.25M-19.55M-22.56M-24.05M-23.00M-25.25M-30.14M-31.66M-29.89M-46.73M-36.98M-36.95M-35.71M-32.19M-28.67M
Income towards Parent Company (Quarter)
-32.91M-25.29M-16.32M-16.16M-15.10M-16.25M-19.55M-22.56M-24.05M-23.00M-25.25M-30.14M-31.66M-29.89M-46.73M-36.98M-36.95M-35.71M-32.19M-28.67M
Net Income towards Common Stockholders (Quarter)
-32.91M-25.29M-16.32M-16.16M-15.10M-16.25M-19.55M-22.56M-24.05M-23.00M-25.25M-30.14M-31.66M-29.89M-46.73M-36.98M-36.95M-35.71M-32.19M-28.67M
Additional items
EPS (Basic) (Quarter)
-23.71-1.27-1.40-0.67-0.63-0.67-0.81-0.93-0.51-0.24-0.38-0.32-0.28-0.25-0.42-0.29-0.28-0.28-0.25-0.22
EPS (Diluted) (Quarter)
-23.71-1.27-1.40-0.67-0.63-0.67-0.81-0.93-0.51-0.24-0.38-0.32-0.28-0.25-0.42-0.29-0.28-0.28-0.25-0.22
Shares Outstanding (Quarter)
1.39M19.88M11.66M23.97M24.06M24.07M24.05M24.23M47.21M94.83M65.60M94.88M113.43M118.70M111.99M129.68M129.73M129.84M129.78M129.91M
Shares Outstanding (Diluted) (Quarter)
1.39M19.88M11.66M23.97M24.06M24.07M24.05M24.23M47.21M94.83M65.60M94.88M113.43M118.70M111.99M129.68M129.73M129.84M129.78M129.91M
EBITDA (Quarter)
-10.68M-15.84M-14.20M-16.16M-15.25M-16.58M-18.65M-22.74M-24.61M-24.75M-21.36M-31.37M-34.11M-32.62M-36.71M-36.25M-38.65M-37.05M-23.86M-29.14M
Interest Expenses (Quarter)
22.23M9.45M2.12M0.20M1.80M0.96M0.97M0.98M6.49M0.96M0.95M0.96M0.78M0.68M0.69M0.70M1.04M0.69M